share_log

Transcode Therapeutics | SC 13D: Statement of acquisition of beneficial ownership by individuals-Thomas A. Fitzgerald(5.5%)

Transcode Therapeutics | SC 13D: Statement of acquisition of beneficial ownership by individuals-Thomas A. Fitzgerald(5.5%)

Transcode Therapeutics | SC 13D:超过5%持股股东披露文件-Thomas A. Fitzgerald(5.5%)
美股SEC公告 ·  06/21 16:09
Moomoo AI 已提取核心信息
Thomas A. Fitzgerald, the Interim CEO, CFO, and a board member of TransCode Therapeutics, Inc., filed a Schedule 13D with the SEC on June 21, 2024, indicating a significant ownership stake in the company. Fitzgerald reported beneficial ownership of 422,036 shares of TransCode Therapeutics' common stock, which represents approximately 5.5% of the company's outstanding shares. This stake includes 1,408 shares held directly and 420,628 shares issuable upon the exercise of stock options within 60 days of the filing date. The filing, which details Fitzgerald's potential influence over corporate activities, also notes his right to acquire additional shares or dispose of his holdings in the future. Fitzgerald's investment decisions are expected to be influenced by a variety of factors, including the company's business prospects and market conditions.
Thomas A. Fitzgerald, the Interim CEO, CFO, and a board member of TransCode Therapeutics, Inc., filed a Schedule 13D with the SEC on June 21, 2024, indicating a significant ownership stake in the company. Fitzgerald reported beneficial ownership of 422,036 shares of TransCode Therapeutics' common stock, which represents approximately 5.5% of the company's outstanding shares. This stake includes 1,408 shares held directly and 420,628 shares issuable upon the exercise of stock options within 60 days of the filing date. The filing, which details Fitzgerald's potential influence over corporate activities, also notes his right to acquire additional shares or dispose of his holdings in the future. Fitzgerald's investment decisions are expected to be influenced by a variety of factors, including the company's business prospects and market conditions.
TransCode Therapeutics,Inc.的临时首席执行官、首席财务官和董事Thomas A. Fitzgerald于2024年6月21日向SEC提交了13D表,表明他在公司拥有重要的所有权。Fitzgerald报告拥有422,036股TransCode Therapeutics普通股的受益所有权,这相当于公司已发行普通股的约5.5%。这个股份包括1,408股直接持有和420,628股在提交日期60天内行使股票期权获得的股份。该申报文件详细说明了Fitzgerald对公司活动的潜在影响,并指出他在未来获得额外股份或处置其持股权的权利。Fitzgerald的投资决策预计会受到各种因素的影响,包括公司的业务前景和市场状况。
TransCode Therapeutics,Inc.的临时首席执行官、首席财务官和董事Thomas A. Fitzgerald于2024年6月21日向SEC提交了13D表,表明他在公司拥有重要的所有权。Fitzgerald报告拥有422,036股TransCode Therapeutics普通股的受益所有权,这相当于公司已发行普通股的约5.5%。这个股份包括1,408股直接持有和420,628股在提交日期60天内行使股票期权获得的股份。该申报文件详细说明了Fitzgerald对公司活动的潜在影响,并指出他在未来获得额外股份或处置其持股权的权利。Fitzgerald的投资决策预计会受到各种因素的影响,包括公司的业务前景和市场状况。
声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息